The Impact of Bryophyllum on Preterm Delivery
The Impact of the Prophylactic or Therapeutic Application of Bryophyllum on Preterm Delivery - a Prospective Study
2 other identifiers
interventional
26
1 country
1
Brief Summary
The purpose of this study is whether Bryophyllum is more effective and has less side effects than traditional labor inhibitors in preventing preterm delivery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jul 2004
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 9, 2005
CompletedFirst Posted
Study publicly available on registry
September 14, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2009
CompletedApril 4, 2019
April 1, 2019
5 years
September 9, 2005
April 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Extension of pregnancy
Secondary Outcomes (1)
Rate of preterm deliveries, rate of side effects, days of hospitalisation, rate of lung maturation.
Study Arms (2)
Bryophyllum
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- All multiple pregnancies Singleton pregnancies with preterm contractions/cervix \< 25mm, or singleton pregnancies with burdened maternal anamnesis (e.g. prior preterm delivery preterm contractions cerclage).
You may not qualify if:
- Fetal malformations
- Chromosomal anomalies
- Intrauterine growth restriction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Obstetrical Unit, Women's University Hospital Basel
Basel, Canton of Basel-City, 4031, Switzerland
Related Publications (3)
Plangger N, Rist L, Zimmermann R, von Mandach U. Intravenous tocolysis with Bryophyllum pinnatum is better tolerated than beta-agonist application. Eur J Obstet Gynecol Reprod Biol. 2006 Feb 1;124(2):168-72. doi: 10.1016/j.ejogrb.2005.05.013. Epub 2005 Jul 26.
PMID: 16051414BACKGROUNDGwehenberger B, Rist L, Huch R, von Mandach U. Effect of Bryophyllum pinnatum versus fenoterol on uterine contractility. Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):164-71. doi: 10.1016/S0301-2115(03)00370-1.
PMID: 15063954BACKGROUNDVilaghy I. [Decreasing the rate of premature delivery with phytotherapy--results from general practice]. Ther Umsch. 2002 Dec;59(12):696-701. doi: 10.1024/0040-5930.59.12.696. German.
PMID: 12584959BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Irène Hoesli, Prof. Dr. MD
Women's University Hospital, Basel, Switzerland
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 9, 2005
First Posted
September 14, 2005
Study Start
July 1, 2004
Primary Completion
July 1, 2009
Study Completion
July 1, 2009
Last Updated
April 4, 2019
Record last verified: 2019-04